NEW YORK (GenomeWeb) – Cepheid reported after the close of the market Thursday that its third quarter revenues increased 25 percent year over year.

The Sunnyvale, California-based molecular diagnostics firm, which signed a deal in September to be acquired by Danaher for around $4 billion, released its earnings through a quarterly report filed with the US Securities and Exchange Commission.